

To Canada's Health Ministers from the Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA)

## **CPMEA Urges Health Ministers to Protect Canada's Domestic Pharmaceutical Production**

As you convene this week in Alberta, the Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) call on our Ministers of Health to make the production of medicines in Canada a priority.

Recent actions by the Trump administration to reshore pharmaceutical manufacturing have created a new competitive challenge for Canada's domestic producers. American policies to promote investment and offer incentives for U.S.-based production will make it increasingly attractive to manufacture south of the border. The EU is also offering strong incentives to build and retain local capacity. Without similar measures, we risk losing domestic production of medicines and the health system security that comes with it.

Canada has become over-reliant on imported medicines, including from non-allied nations. This dependence leaves Canadians vulnerable to geopolitical disruptions, trade disputes, and supply chain shocks. If we cannot produce enough medicines domestically, our healthcare system is at risk.

We ask you to recognize pharmaceutical manufacturing as a critical industry, essential for our public health security and to take concrete steps to secure Canada's medicine supply.

The Alliance calls upon the Ministers of Health to treat pharmaceutical production as a national security priority and ensure Canada's ability to supply its population is equal to what the U.S. and EU are doing. We recommend:

- **'Canada First' formulary listings** for Canadian-made medicines
- **'Canada First' exclusivity period** for newly launched generic products made in Canada
- **'Canada First' priority review** for drug submissions to Health Canada for Canadian manufacturers
- **Guidance to hospital buying groups** to prioritize procurement from Canadian pharmaceutical manufacturers
- **Competitive tax policies and refundable manufacturing credits** to retain and attract pharmaceutical production

Canada must preserve the manufacturing base we have and provide incentives for future growth. At your meeting in Alberta, we ask you to take the opportunity to work together to strengthen the resilience of our healthcare system by making domestic production a cornerstone of Canada's health strategy.

We would be happy to meet with you and your staff to discuss the details of these proposals.

Sincerely,



Terry Creighton

President

Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA)

[Terry.creighton@cpmea.ca](mailto:Terry.creighton@cpmea.ca)

416.904.1711

[www.cpmea.ca](http://www.cpmea.ca)

---

### **About the Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA)**

The Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) – Alliance fabricants et exportateurs pharmaceutiques du Canada (AFEPC) represents pharmaceutical companies that manufacture in Canada. Our members are the largest producers of medicines by volume making essential medicines for Canadian patients and for export. At this critical time, we have come together to raise awareness of the challenges facing our industry and put forward positive solutions to ensure Canada's future sovereignty of supply of medicines.